Citation & Authors
J Am Acad Dermatol. 2025;92(5):1015-1023.
ABSTRACT · RESEARCH SUMMARY
Research summary
The study included 32,098 biologic-naive patients with psoriasis or psoriatic arthritis and used target trial emulation to compare IL-17, IL-12/23, IL-23, and TNF inhibitors. Overall risks of major adverse cardiovascular events and venous thromboembolism did not differ significantly, although differences appeared in some metabolic comorbidity subgroups. Psoriasis severity was unavailable, and unmeasured confounding must be considered.
Key points based on the public abstract; this is a reading guide, not a full abstract translation.Read original abstract ↗
